Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H34N2O8 |
| Molecular Weight | 490.5461 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)OCCOCCC
InChI
InChIKey=VZWXXKDFACOXNT-UHFFFAOYSA-N
InChI=1S/C25H34N2O8/c1-5-10-32-12-14-34-24(28)21-17(3)26-18(4)22(25(29)35-15-13-33-11-6-2)23(21)19-8-7-9-20(16-19)27(30)31/h7-9,16,23,26H,5-6,10-15H2,1-4H3
Niludipine (Bay-a-7168) is a potent calcium antagonistic coronary vasodilator with less cardiodepressant effect than nifedipine. Niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris. Niludipine is clinically useful as coronary vasodilator and hypotensive agent.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute and chronic hypotensive effects of nifedipine and niludipine in hypertensive patients with chronic renal failure. | 1984 |
|
| Effects of Ca antagonists, nifedipine, niludipine and verapamil, on endocrine function of the pancreas. | 1983-06 |
|
| Effects of new calcium channel blocker of niludipine on the coronary hemodynamics, diastolic properties, and metabolic responses to tachycardia stress in patients with coronary disease. | 1982 |
|
| Comparative coronary vasodilatory effects of nifedipine and niludipine. | 1981 |
|
| Antihypertensive effect of Niludipine (Bay a 7168) on conscious renal-hypertensive dogs. | 1979 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6791665
Angina pectoris: Oral administration of from 60--120 mg niludipine daily for 4--8 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6171682
Curator's Comment: Effects of niludipine on isolated rabbit sinus node and right atrial preparations were studied using intracellular microelectrode techniques.
Niludipine in concentrations above 1 X 10(-8) M caused dose-dependent changes in the membrane action potentials of the preparations. Little change occurred in the MDP and MRD of atrial muscle fibers even at the highest concentration (1 X 10(-6) M).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB09240
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
C76581
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
SUB09290MIG
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
245-120-6
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
4319
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
89767
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
9844OS3B0J
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
Niludipine
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
100000083902
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106840
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
22609-73-0
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY | |||
|
DTXSID20945267
Created by
admin on Mon Mar 31 18:25:25 GMT 2025 , Edited by admin on Mon Mar 31 18:25:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY